A new Georgia biotech facility could change how the world gets vaccinated. Micron Biomedical just celebrated the grand opening of its Alpharetta manufacturing site, where the clinical-stage company is scaling up a dissolvable microarray patch designed to replace the traditional syringe-and-vial vaccine model. The technology is still working its way through clinical trials. Still, the implications stretch from local pediatricians’ offices to remote villages without a refrigerator in sight.
Here’s how the technology works and why it matters:
- Micron’s platform places vaccine or therapeutic medication onto a small, Band-Aid-sized patch lined with microscopic “microneedles.”
- When pressed to the skin, the microneedles dissolve and release the medication directly into the body, no syringe, no sharps disposal, no clinical setup required.
- The patches use a dried form of the vaccine that’s stable at room temperature, sidestepping the cold-chain logistics that make global immunization campaigns so expensive and fragile.
A win for the needle-averse
Roughly one in four adults reports significant needle phobia, and the number climbs higher in pediatric populations. For patients who’ve quietly skipped vaccinations for years to avoid a syringe, a painless adhesive patch reframes the entire experience. It also opens the door to better compliance on boosters and seasonal vaccines, where avoidance compounds over time.
Rural and remote access, reimagined
Traditional liquid vaccines require trained personnel, refrigeration, and physical access to a clinic, a combination that’s chronically scarce in rural America and much of the developing world. Micron’s patch is simple enough to apply that, in theory, doses could be mailed directly to households or distributed by non-medical community health workers. That shifts vaccination from a clinical event to something closer to picking up a prescription at the mailbox.
On Background: Cold-chain failures are among the most persistent and expensive problems in global immunization. The WHO has long estimated that a meaningful share of vaccines spoil before reaching patients due to refrigeration gaps. A room-temperature-stable patch doesn’t just simplify shipping; it changes the economics of who can be reached at all.
The bigger picture for Georgia
Micron’s Alpharetta footprint lands as Georgia continues to position itself as a national hub for commercial-scale biomanufacturing. The state has spent the last several years courting pharmaceutical, cell therapy, and medical device manufacturers, drawn by its logistics network, research universities, and growing biotech workforce. Micron joins that lineup as a flagship example of homegrown innovation moving from the lab bench to the manufacturing floor within state lines.
What’s next? The technology still has to clear clinical trials and regulatory review before patients see it on pharmacy shelves. Still, the Alpharetta facility signals that Micron is preparing for the day approval lands. If the platform performs as promised, the company’s microarray patches could become one of the more consequential exports of Georgia’s biotech ecosystem, with applications that reach far beyond the state line.
Micron Biomedical Company Profile
Website: micronbiomedical.com
Located: Alpharetta, Georgia
Founded: 2014
Team: 25 Employees
Awards: Named to Fast Company’s 2026 World’s Most Innovative Companies list — recognized as the #2 most innovative company in its category.
Notable Technology & Services: Dissolvable Microarray Vaccines And Therapeutics
- Thermostable (no cold-chain refrigeration required)
- Enables simplified global distribution
- Compatible with vaccines for influenza, polio, measles-rubella, and other indications
- Designed for use cases ranging from pediatric immunization to pandemic preparedness (“Disease X”)
